| Theme | Therapeutic strategy for Crohn's disease -- Should mucosal healing be a final goal? | |
|---|---|---|
| Title | Current role of mesalazine and corticosteroids in treatment of Crohn's disease | |
| Publish Date | 2012/05 | |
| Author | Masakazu Nagahori | Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University |
| [ Summary ] | With the changes that have come about in treatment goals we must re-consider the role of "conventional treatments" for Crohn's disease. When previous clinical trials are evaluated in a critical manner, we were forced to admit that the role of mesalazine in treatment of Crohn's disease is considerably limited. The efficacy of corticosteroids as a form of induction therapy is unquestionable. After the initiation of corticosteroids, however, questions may arise as to when aggressive immunosuppression, such as immunomodulators or biologics or both should be used. | |